A New Treatment Strategy that Reduces Growth/Differentiation Factor-15 in Type-2 Diabetes Mellitus: Major Autohemotherapy: A Pilot Study
Yazarlar (2)
Doç. Dr. Hasan Esat YÜCEL Kırşehir Ahi Evran Üniversitesi, Türkiye
Doç. Dr. Bilal İLANBEY Kırşehir Ahi Evran Üniversitesi, Türkiye
| Makale Türü |
Özgün Makale
(SCOPUS dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE | ||
| Dergi ISSN | 1078-6791 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | Türkçe | Basım Tarihi | 10-2023 |
| Kabul Tarihi | 12-04-2026 | Yayınlanma Tarihi | – |
| Cilt / Sayı / Sayfa | 29 / 7 / 30–33 | DOI | – |
| Makale Linki | http://alternative-therapies.com/abstract/index.html?id=106153 | ||
| Özet |
| Context• Growth/differentiation factor-15 (GDF-15) is a diagnostic and prognostic marker associated with inflammation, renal damage, and cardiovascular risk in type-2 diabetes mellitus. Researchers have proposed treatment targets that reduce GDF-15 levels. Objective• Our aim in this study is to investigate the effect of major autohemotherapy on GDF-15 levels and to evaluate it as a complementary therapy. Design• The research team designed a laboratory study to examine the effect of major hemotherapy on GDF-15 levels in patients with type-2 diabetes mellitus and healthy volunteers. Blood was drawn from the participants in a closed system, infused with ozone gas, and reinfused into the patients. |
| Anahtar Kelimeler |
